Goldridge Terminal ロゴ Goldridge Terminal
人気
ログイン

ウォッチリストに追加
Proチャート

ARS Pharmaceuticals Inc.

NasdaqGM: SPRY · リアルタイム株価 · USD
6.10
+0.05 (0.83%)
終値時点： Aug 13, 2026, 3:59 PM
5.28
-13.46%
時間外: 7:58 PM

ARS Pharmaceuticals Inc. (SPRY) Stock Price, Analysis & Data

0.83%
買気配3.89
時価総額605.75M
売上高（TTM）98.99M
純利益（TTM）-197.98M
ベータ0.97
EPS（TTM）-2
PER（TTM）n/a
予想PER-6.47
PBR（TTM）9.89
PSR（TTM）6.12
Earnings DateAug 13, 2026
売気配6.72
出来高1,944,858
平均出来高（20日）2,035,241
始値6.12
前日終値6.05
当日レンジ5.90 - 6.19
52週レンジ4.91 - 15.71
アナリストn/a
目標株価27 (342.62%)
配当n/a
権利落ち日n/a

SPRYについて

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California....

[続きを読む]
業種 Biotechnology
セクター Healthcare
IPO日 Dec 4, 2020
従業員数 154
上場取引所 NasdaqGM
ティッカー SPRY
ウェブサイト https://ars-pharma.com
企業情報の全文

業績

2025年のARS Pharmaceuticalsの売上高は84.28Mで、前年の89.15Mから-5.46%の減少でした。 利益は-171.3Mで、-2,241.76%の減少でした。

財務諸表

アナリスト予想

4件のアナリスト評価によると、SPRY株の平均レーティングは「null」です。12か月後の目標株価は27で、直近株価から342.62%の上昇余地となります。

株価予想

決算サプライズ

ARS PharmaceuticalsはMay 15, 2026に四半期決算を発表しました：
  • 売上高は $22.68M で、予想を下回りました $0, うち 184.47% の前年比増加にあたります.
  • EPSは -0.61 で、予想を下回りました -0.08, うち -74.29% の前年比減少.

    • 次回決算発表

    ARS Pharmaceuticals Inc.の決算発表予定日は Aug 13, 2026, 引け後の予定です。
    アナリストの売上高予想は ... アップグレード
    news image

    たった今 · Zacks

    ARS Pharmaceuticals, Inc. (SPRY) Reports Q2 Loss, Tops Revenue Estimates

    ARS Pharmaceuticals, Inc. (SPRY) delivered earnings and revenue surprises of -14.55% and +5.54%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the sto...

    news image

    1週間前 · Zacks

    Cronos Group (CRON) Surpasses Q2 Earnings and Revenue Estimates

    Cronos (CRON) delivered earnings and revenue surprises of +200.00% and +24.11%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

    news image

    4週間前 · Insider Monkey

    ARS Pharmaceuticals (SPRY) Appoints Donn Casale As The New CEO

    ARS Pharmaceuticals Inc. (NASDAQ:SPRY) is one of the 10 best stocks under $10 that could triple. On July 8, ARS Pharmaceuticals Inc. (NASDAQ:SPRY) disclosed a CEO transition, and effective July 6, the...

    news image

    1か月前 · Zacks

    Strength Seen in CRINETICS PHARM (CRNX): Can Its 98.7% Jump Turn into More Strength?

    CRINETICS PHARM (CRNX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near t...

    news image

    1か月前 · Simply Wall St.

    ARS Pharmaceuticals (SPRY) Is Down 11.5% After Losing Spots in Key Russell 2000 Defensive Indices

    In late June 2026, ARS Pharmaceuticals, Inc. (NasdaqGM: SPRY) was removed from both the Russell 2000 Growth-Defensive Index and the Russell 2000 Defensive Index, altering its presence in widely follow...

    2ページ中1ページ